SAKK-EORTC-10994, NCT00017095: Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer |
|
|
| Completed | 3 | 1856 | Europe | filgrastim, cyclophosphamide, docetaxel, epirubicin hydrochloride, fluorouracil, microarray analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy | European Organisation for Research and Treatment of Cancer - EORTC, Swedish Breast Cancer Group, Swiss Group for Clinical Cancer Research, Anglo Celtic Cooperative Oncology Group | Breast Cancer | 11/06 | | | |
| Completed | 3 | 1500 | Europe | trastuzumab, capecitabine, cyclophosphamide, docetaxel, epirubicin hydrochloride, adjuvant therapy, conventional surgery, neoadjuvant therapy | German Breast Group | Breast Cancer | | | | |
GeparOcto, NCT02125344 / 2014-000619-14: A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer |
|
|
| Completed | 3 | 961 | Europe | non-pegylated liposomal doxorubicin, Myocet, Carboplatin, Carbomedac, Paclitaxel, var., Epirubicin, Farmorubicin, Cyclophosphamide, Endoxan, Pertuzumab, Perjeta, Trastuzumab, Herceptin, Ferric carboxymaltose, Ferinject | German Breast Group, Amgen, Roche Pharma AG, Teva Pharmaceuticals USA, Vifor Pharma | Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, HER2 Positive Breast Cancer, Inflammatory Breast Cancer | 11/16 | 01/17 | | |
